Dear Colleagues

It is with great pleasure that we welcome you to participate in the 18th Annual Superbugs & Superdrugs conference taking place on 16th -17th March 2016, Central London, UK.

Antimicrobial resistance is clearly a serious global threat. To combat potential epidemic, requires both industry and government collaboration on an international level in antibiotics R&D investments, preventive measures and emergency response. As new resistance mechanisms rapidly spread throughout the developed and developing nations, this is putting our existing antibiotic pipeline under greater higher risk of failing to resolve many standard medical treatments, as well as compromising our achievements in modern standard medicine including cancer therapeutics and surgery. To curb an uncontrollable outbreak 'storm', we urge committed action and international stewardship from the industry to drive anti-superbugs and superdrug developments.

We are delighted to chair this annual industry meeting in 2016 again, which will gather a high level of international experts and project decision makers in a timely opportunity to discuss ongoing challenges and lay the foundation for innovations that will enhance the security and R&D projects for novel therapies in anti-infectives.

Please take time to peruse the conference agenda which has been drafted with great care to give you the very best opportunity to benchmark and learn from subject matter experts in infectious diseases, health economics and advanced technologies and solutions. Networking and learning with our peers is the secret to improving the drug development pipeline. With practical case studies and interactive roundtables, there is confidence that we will be able to crack the 'chicken or the egg' problem.

Yours Sincerely,



Richard P. Bax

Richard Bax, Senior Partner, Transcrip Partners



L. Gaplune.

Lloyd Czaplewski, Director, Chemical Biology Ventures Ltd